{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:53:20Z","timestamp":1720094000432},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T00:00:00Z","timestamp":1112832000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Vaccination with fusion cells (FCs) comprising dendritic cells and tumour cells as well as administration of interleukin\u201012 (IL\u201012) showed a significant therapeutic effect against established tumours in mouse experimental models. We conducted immunotherapy against various malignant tumours using the FCs and rhIL\u201012, and investigated the safety and efficacy of the therapy.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold> Patients\u2019 DCs were mixed with autologous irradiated tumour cells and treated with 50% polyethylene glycol to generate FCs. The FCs were inoculated intradermally, and then 30\u00a0ng\u00a0kg<jats:sup>\u22121<\/jats:sup> of rhIL\u201012 was injected at the same sites 2 and 6\u00a0days later. This process was carried out as one cycle, and three of these cycles were repeated at 1\u2010week intervals to comprise one course. After completing the course, its safety and therapeutic effects were estimated.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The most frequently observed adverse event was fever, observed in 26% of patients in the first cycle. Decrease in white blood cell and an increase in serum ALT were observed in 28% and 25%, respectively. Three out of 12 patients with a malignant brain tumour (25%) achieved a partial response (PR), but other patients with a malignant tumour showed no regression of their tumours. Thirteen out of 16 patients with a brain tumour (81%) showed cutaneous delayed hypersensitivity responses. However, only one of 16 patients (6%) with a malignant tumour other than a brain tumour developed such responses.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Immunotherapy using a FC vaccine and rhIL\u201012 induced no serious adverse reactions, and provided good therapeutic responses in some of the patients with a brain tumour.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2005.01494.x","type":"journal-article","created":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T14:32:09Z","timestamp":1112884329000},"page":"279-286","source":"Crossref","is-referenced-by-count":29,"title":["Cancer immunotherapy by fusions of dendritic and tumour cells and rh\u2010IL\u201012"],"prefix":"10.1111","volume":"35","author":[{"given":"S.","family":"Homma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ishiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Saotome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kufe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,4,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)84664-6"},{"key":"e_1_2_6_3_2","first-page":"173","article-title":"Cytotoxic lymphocytes. redirecting the cell\u2010mediated immune response for the therapy of cancer","volume":"2","author":"Kershaw MH","year":"1995","journal-title":"Ther Immunol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.09.040191.001415"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/32588"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050317"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.8.1183"},{"key":"e_1_2_6_8_2","first-page":"54","article-title":"Current issues in dendritic cell cancer immunotherapy","volume":"4","author":"Lopez JA","year":"2002","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1039"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1109"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.283"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.4049\/jimmunol.161.10.5607","article-title":"Generation of melanoma\u2010specific cytotoxic T lymphocytes by dendritic cells transduced with a MART\u20101 adenovirus","volume":"161","author":"Butterfield LH","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.1185"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2501"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0597-558"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.5.2111"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.10.5317"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620100205"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303403321467243"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0347"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200103000-00004"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005350170019"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2003.01194.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17323"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20247"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/6.1.157"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4049\/jimmunol.160.4.1638","article-title":"IL\u201012 receptor (IL\u201012R) expression and accumulation of IL\u201012R\u03b21 and IL\u201012R\u03b22 mRNA in CD4+T cells by costimulation with B7\u20132 molecules","volume":"160","author":"Igarashi O","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_6_28_2","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin\u201012 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer RJ","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_29_2","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_30_2","first-page":"2661","article-title":"A dose\u2010escalation and pharmacokinetic study of subcutaneously administered recombinant human interkeukin 12 and its biological effects in Japanese patients with advanced malignancies","volume":"6","author":"Ohno R","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.09.045"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200411000-00005"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02700015"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.2741\/1465"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200403000-00008"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2005.01494.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2005.01494.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:26:52Z","timestamp":1697214412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2005.01494.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1365-2362.2005.01494.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2005.01494.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}